Research Site
Philadelphia, Pennsylvania, United States
NCT Number: NCT00726427
The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Philadelphia, Pennsylvania, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dose escalation to achieve maximum tolerated dose
Time frame: Safety variables taken repeatedly during 24 hours on study day sessions
Time frame: Pharmacokinetic variables taken repeatedly during 24 hours on study day sessions
Time frame: Blood samples taken repeatedly during 24 hours on study day sessions
AstraZeneca
Industry
A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details